Ariad Pharmaceuticals said today it lost a patent lawsuit filed against Amgen, the world’s largest biotechnology company. Cambridge, MA-based Ariad (NASDAQ: [[ticker:ARIA]]) the U.S. District Court in Delaware said Amgen’s rheumatoid arthritis drug Enbrel doesn’t infringe on Ariad’s patent on reducing NF-(kappa) B activity. Ariad holds an exclusive license on the patent, called ‘516, from discoveries by David Baltimore, Phillip Sharp and Tom Manaitis at MIT, the Whitehead Institute for Biomedical Research, and Harvard University. Ariad CEO Harvey Berger said the company plans to pursue “appropriate legal action” to review the court’s decision.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
